Cost-effectiveness of everolimus-versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV trial)

American Journal of Cardiology

Volumn 110, Issue 6, 2012, Pages 765-770

  Amin, Amit P ^a,b   Reynolds, Matthew R ^c   Lei, Yang ^a   Magnuson, Elizabeth A ^a   Vilain, Katherine ^a   Durtschi, Amy J ^d   Simonton, Charles A ^d   Stone, Gregg W ^e   Cohen, David J ^a,b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d ABBOTT VASCULAR   (United States)

^e Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; PACLITAXEL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PACLITAXEL ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SIROLIMUS; UNITED STATES;

EID: 84865518812     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.05.006     Document Type: Article

References (18)

1. G.W. Stone, A. Rizvi, W. Newman, K. Mastali, J.C. Wang, R. Caputo, J. Doostzadeh, S. Cao, C.A. Simonton, K. Sudhir, A.J. Lansky, D.E. Cutlip, D.J. Kereiakes SPIRIT IV Investigators Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
2. U.S. Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes Consumer Price index, 2010 http://www.bls.gov/cpi/tables.htm
3. A. Bakhai, G.W. Stone, E. Mahoney, T.A. Lavelle, C. Shi, R.H. Berezin, B.J. Lahue, M.A. Clark, M.J. Lacey, M.E. Russell, S.G. Ellis, J.B. Hermiller, D.A. Cox, D.J. Cohen TAXUS-IV Investigators Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV trial J Am Coll Cardiol 48 2006 253 261
4. D.J. Cohen, A. Bakhai, C. Shi, L. Githiora, T. Lavelle, R.H. Berezin, M.B. Leon, J.W. Moses, J.P. Carrozza Jr, J.P. Zidar, R.E. Kuntz SIRIUS Investigators Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial Circulation 110 2004 508 514
5. ACC NCDR® CathPCI Registry® https://www.accncdr.com/webncdr/ DefaultCathPCI.aspx Accessed March 20, 2011
6. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services http://www.cms.gov/MedicareFeeforSvcPartsAB/03-MEDPAR.asp Accessed on March 31, 2011
7. G.W. Stone, A. Rizvi, K. Sudhir, W. Newman, R.J. Applegate, L.A. Cannon, J.T. Maddux, D.E. Cutlip, C.A. Simonton, P. Sood, D.J. Kereiakes SPIRIT IV Investigators Randomized comparison of everolimus- and paclitaxel-eluting stents 2-Year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25
8. D.J. Cohen, D.A. Taira, R. Berezin, D.A. Cox, M.C. Morice, G.W. Stone, C.L. Grines Cost effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) trial Circulation 104 2001 3039 3045
9. A. Briggs, P. Fenn Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane Health Econ 7 1998 723 740
10. A.A. Stinnett, J. Mullahy Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis Med Decis Making 18 suppl 1998 S68 S80
11. E.L. Eisenstein, M.B. Leon, D.E. Kandzari, L. Mauri, R. Edwards, D.F. Kong, P.A. Cowper, K.J. Anstrom Long-term clinical and economic analysis of the endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial JACC Cardiovasc Interv 2 2009 1199 1207
12. K. Rasmussen, M. Maeng, A. Kaltoft, P. Thayssen, H. Kelbaek, H.H. Tilsted, U. Abildgaard, E.H. Christiansen, T. Engstrøm, L.R. Krusell, J. Ravkilde, P.R. Hansen, K.N. Hansen, S.Z. Abildstrøm, J. Aarøe, J.S. Jensen, S.D. Kristensen, H.E. Bøtker, M. Madsen, S.P. Johnsen, L.O. Jensen, H.T. Sørensen, L. Thuesen, J.F. Lassen SORT OUT III Study Group Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
13. D.W. Park, Y.H. Kim, S.C. Yun, S.J. Kang, S.W. Lee, C.W. Lee, S.W. Park, I.W. Seong, J.H. Lee, S.J. Tahk, M.H. Jeong, Y. Jang, S.S. Cheong, J.Y. Yang, D.S. Lim, K.B. Seung, J.K. Chae, S.H. Hur, S.G. Lee, J. Yoon, N.H. Lee, Y.J. Choi, H.S. Kim, K.S. Kim, H.S. Kim, T.J. Hong, H.S. Park, S.J. Park Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 2010 1187 1195
14. M.B. Leon, D.E. Kandzari, E.L. Eisenstein, K.J. Anstrom, L. Mauri, D.E. Cutlip, E. Nikolsky, C. O'Shaughnessy, P.A. Overlie, A.J. Kirtane, B.T. McLaurin, S.L. Solomon, J.S. Douglas Jr, J.J. Popma Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial JACC Cardiovasc Intv 2 2009 1208 1218
15. S.J. Brener, A.J. Prasad, Z. Khan, T.J. Sacchi The relationship between late lumen loss and restenosis among various drug-eluting stents: a systematic review and meta-regression analysis of randomized clinical trials Atherosclerosis 214 2011 158 162
16. D.S. Pinto, G.W. Stone, S.G. Ellis, D.A. Cox, J. Hermiller, C. O'Shaughnessy, J.T. Mann, R. Mehran, Y. Na, M. Turco, R. Caputo, J.J. Popma, D.E. Cutlip, M.E. Russell, D.J. Cohen TAXUS-IV Investigators Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial J Am Coll Cardiol 48 2006 32 36
17. P.N. Ruygrok, R. Melkert, M.A. Morel, J.A. Ormiston, F.W. Br, F. Fernandez-Avils, H. Suryapranata, K.D. Dawkins, C. Hanet, P.W. Serruys Does angiography six months after coronary intervention influence management and outcome? Benestent II investigators J Am Coll Cardiol 34 1999 1507 1511
18. T. Uchida, J. Popma, G.W. Stone, S.G. Ellis, M.A. Turco, J.A. Ormiston, T. Muramatsu, M. Nakamura, S. Nanto, H. Yokoi, D.S. Baim The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions JACC Cardiovasc Interv 3 2010 403 411